Mualliflar

  • Axmatova K.A., Azizova D.M., Oxunjonov E.R.

##semicolon##

multifokal ateroskleroz, kalsifikatsiya, proprotein konvertaza subtilizin keksin 9 tip, lipoil kislota, yalligʻlanish, YuIK, ZPLP retseptori.

##submission.citations##

1. Кочкаров В.И., Буравлева С.В., Покровский М.В. и др. Эндотелиопротективное действие препаратов тиоктовой кислоты // Приволжский науч. вестн. – 2011. – №2. – С. 84-88.

2. Almontashiri N.A., Vilmundarson R.O., Ghasemzadeh N. et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independents retrospective angiographic studies // PLoS ONE. – 2014. – Vol. 9. – Р. e106294. doi: 10.1371/journal. pone.010 6294

3. Al-Nami M.S., Al-Kuraishy H.M., Al-Gareeb A.I. Impact of thioctic acid on glycemic indices and associated inflammatory-induced endothelial dysfunction in patients with type 2 diabetes mellitus: A case control study // Int. J. Crit. Illness and Injury Sci. – 2020. – Vol. 145. http://www.ijciis.org S21-S-27

4. Boyd J.H., Fjell C.D., Russell J.A. et al. Increased Plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis // J. Innate Immun. – 2016. – Vol. 8. – Р. 211-220. doi: 10.1159/000442976

5. Cheng J.M., Oemrawsingh R.M., Garcia-Garcia H.M. et al. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study // Atherosclerosis. – 2016. – Vol. 248. – Р. 117-122. doi: 10.10 16/j.atherosclerosis.2016.03.010

6. Ding Z., Liu S., Wang X. et al. Crosstalk between LOX-1 and PCSK9 in vascular tissues // Cardiovasc. Res. – 2015. – Vol. 107. – Р. 556-567. doi: 10.1093/cvr/cvv178

7. Dozio E., Ruscica M., Vianello E. et al. PCSK9 expression in epicardial adipose tissue: molecular association with local tissue inflammation // Mediators Inflamm. – 2020. – Vol. 2020. – Р. 1348913. doi: 10.1155/2020/134 8913

8. Fernandez-Friera L., Fuster V., Lopez-Melgar B. et al. Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI // J. Amer. Coll. Cardiol. – 2019. – Vol. 73. – Р. 1371-1382. doi: 10.1016/j.jacc. 2018.12.075

9. Ferri N., Marchiano S., Tibolla G. et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement // Atherosclerosis. – 2016. – Vol. 253. – Р. 214-224.doi: 10.10 16/j.atherosclerosis. 2016.07.910

10. Gencer B., Montecucco F., Nanchen D. et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes // Eurор. Heart J. – 2016. – Vol. 37. – Р. 546-553. doi: 10.1093/eurheartj/ehv637

11. Giunzioni I., Tavori H., Covarrubias R. et al. Local effects of human PCSK9 on the atherosclerotic lesion // J. Pathol. – 2016. – Vol. 238. – Р. 52-62. doi: 10.1002/path.4630

12. Heinzl M.W., Resl M., Klammer C. et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is not induced in artificial human inflammation and is not correlated with inflammatory response // Infect. Immun. – 2020. – Vol. 88. – piie00842-19. doi: 10.1128/ IAI.00842-19

13. Hossain E., Ota A., Karnan S. et al. Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages // Mol. Cell. Biochem. – 2015. – Vol. 400. – Р. 29-40. doi: 10.1007/s11010-014-2259-0

14. Jialal I., Devaraj S., Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis // Hypertension. – 2004. – Vol. 44. – Р. 6-11. doi: 10.1161/01.HYP.00001 30484.20501.pdf

15. Kaptoge S., Di Angelantonio E. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis // Lancet. – 2010. –Vol. 375. – Р. 132-140. doi: 10.1016/S0140-6736(09)61717-7

16. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy // Int. J. Cardiol. – 2013. – Vol. 168. – Р. 5126-134. doi: 10.1016/j.ijcard.2013.07.113

17. Kuhnast S, van der Hoorn JWA, Pieterman EJ, van den Hoek AM, Sasiela WJ, Ali S, et al. Alirocumab inhibits atherosclerosis, improves plaque morphology, and enhances the effects of a statin. Journal of Lipid Research. 2014;55(10):2103–2112. DOI: https://doi. org/10.1194/jlr.M051326

18. Landlinger C, Pouwer MG, Juno C, van der Hoorn JWA, Pieterman EJ, Jukema JW, et al. The AT04A vaccine against PCSK9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden. CETP mice. European Heart Journal. 2017;38 (32):2499–2507. DOI: https://doi.org/10.10 93/eurheartj/ehx260

19. Li S., Guo Y.L., Xu R.X. et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease // Atherosclerosis. – 2014. – Vol. 234. – Р. 441-445. doi: 10.10 16/j.atherosclerosis.2014.04.001

20. Li S., Zhang Y., Xu R.X. et al. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease // Ann. Med. – 2015. – Vol. 47. – Р. 38 6-393. doi: 10.3109/07853890.2015.10429 08

21. Pirillo A., Norata G.D., Catapano A.L. LOX-1, OxLDL, and atherosclerosis // Mediators Inflamm. – 2013. – Vol. 2013. – Р. 152786. doi: 10.1155/2013/152786

22. Pradhan A.D., Aday A.W., Rose L.M., Ridker P.M. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy // Circulation. – 2018. – Vol. 138. – Р. 141-914. doi: 10.1161/circulationaha.118.03 4645

23. Ruparelia N., Chai J.T., Fisher E.A., Choudhury R.P. Inflammatory processes in cardiovascular disease: a route to targeted therapies // Nat. Rev. Cardiol. – 2017. – Vol. 14. – 133-144. doi: 10.1038/nrcardio.2016. 185

24. Shapiro M.D., Fazio S. PCSK9 and atherosclerosis – lipids and beyond // J. Atheroscler. Thromb. – 2017. – Vol. 24. – Р. 462-472. doi: 10.5551/jat.RV17003

25. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance // J. Biol.Chem. – 1997. – Vol. 272. – Р. 20963-20966. doi: 10.1074/jbc.272.34.20963

26. Sun H, Krauss RM, Chang JT, Teng BB. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction. Journal of Lipid Research. 2018; 59(2):207–223. DOI: https://doi.org/10.1194 /jlr.M078360

27. Sun H.L., Wu Y.R., Song F.F. et al. Role of PCSK9 in the development of mouse periodontitis before and after treatment: a double edged sword // J. Infect. Dis. – 2018. – Vol. 21 7. – Р. 667-680. doi

28. Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, et al. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovascular Research. 2016;110(2):268–278. DOI: https: //doi.org/10.1093/cvr/cvw053

29. Xie W., Liu J., Wang W. et al. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study // Int. J. Cardiol. – 2016. –Vol. 215. – Р. 293-298. doi: 10.1016/ j.ijcard.2016.04.103

30. Zhang Y., Zhu C.G., Xu R.X. et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease // J. Clin. Lipidol. – 2014. – Vol. 8. – Р. 494-500. doi: 10.1016/j.jacl.2014.07.001